Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
about
Structured treatment interruptions (STI) in chronic suppressed HIV infection in adultsStimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionInefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivoComplement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionIn vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapyLow human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virusQuantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDSCD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruptionInterrupting highly active antiretroviral therapy in patients with HIV.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapyAssociation between specific HIV-1 Env traits and virologic control in vivo.Interpreting the effect of vaccination on steady state infection in animals challenged with Simian immunodeficiency virusModel with two types of CTL regulation and experiments on CTL dynamics.No evidence for competition between cytotoxic T-lymphocyte responses in HIV-1 infection.
P2860
Q24245709-B7CAA299-7A91-46E5-B2DC-0597A8F546C1Q24536249-D58EA374-C9F5-453B-A360-BA59CEF73F55Q25255777-8A0D02D9-07F1-42A8-8EEE-9965A4C9B1AAQ28766705-EEEEB7B7-9F95-4042-AA58-B8532F26AF66Q33618013-C78A87FE-8AD5-4DAD-9DC5-64BE71A45676Q33638320-7870EE12-AFB6-40E8-9B71-E5A106BC41C2Q33737646-637AF0A7-463E-4411-B9C9-25764AC1F827Q33883813-AF69EA70-6B36-415E-B24A-D7912E650575Q34227596-34A9573A-CA29-44FE-B57F-E5922755CBAFQ34270951-EDD37075-5BEE-48E1-8A93-8CF3EC08DDCAQ34339925-94050067-D04E-4CE1-AC39-4FB069461A92Q35115062-3C9B31F6-9741-4DE4-BD63-53EA9A969A26Q35205571-0C23A897-ACFD-43C4-87E1-F9AA6365350CQ36066209-F24CFF7E-A958-4E8A-8201-09C2626683BFQ36298503-49F9F8E1-AC3D-4F6D-BB85-4693255EEEE1Q36498230-C0AFEEF7-FFDA-470E-B347-2A497D8236E7Q37570117-4F58F194-BD4B-4BAB-AD93-5FF88AC23F10Q39239465-034F4505-5355-4E2D-BAC0-CBE747E04D2BQ39240571-68019B77-761C-4D82-952C-1C3A00930430Q55398991-0A0E820E-CEEF-4A33-B58B-8E38DAD20C3C
P2860
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Human immunodeficiency virus-specific CD8
@nl
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@ast
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@en
type
label
Human immunodeficiency virus-specific CD8
@nl
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@ast
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@en
prefLabel
Human immunodeficiency virus-specific CD8
@nl
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@ast
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@en
P2093
P2860
P50
P1433
P1476
Human immunodeficiency virus-s ...... ittent antiretroviral therapy.
@en
P2093
Angela R McLean
Christine Schneider
Helen Joller
Marek Fischer
Rainer Weber
Rodney E Phillips
Roland Hafner
Sarah J Dawson
Swiss HIV Cohort Study Group
P2860
P304
10169-10176
P356
10.1128/JVI.76.20.10169-10176.2002
P407
P577
2002-10-01T00:00:00Z